Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2006 on request of the sponsor.

On 30 June 2003, orphan designation (EU/3/03/146) was granted by the European Commission to Chiron B. V., the Netherlands, for aldesleukin (inhalation use) for the treatment of renal cell carcinoma.

The sponsorship was transferred to Chiron Corporation Limited, United Kingdom, in November 2005.

Key facts

Active substance
Aldesleukin (inhalation use)
Disease / condition
Treatment of renal-cell carcinoma
Date of first decision
EU designation number

Sponsor's contact details

Chiron Corporation Limited
Symphony House
7 Cowley Business Park, High Street
Cowley, Uxbridge
United Kingdom
Telephone: +44 20 85 80 40 00
Telefax: +44 20 85 80 40 97

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating